Monopar receives licence to develop Onxeo ’s Validive oral mucositis treatment
Onxeo has granted a global exclusive licence to Monopar Therapeutics for its Validive (clonidine mucoadhesive buccal) tablet used to treat severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Clonidine | Head and Neck Cancer | Oral Cancer | Pharmaceuticals